Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy

L. J. Laslett, A. N. DeMaria, Ezra A Amsterdam, D. T. Mason

Research output: Contribution to journalArticle

Abstract

Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates. Coronary care unit admission with Swan-Ganz catheterization corrected hemodynamics by sodium nitroprusside treatment after hydralazine withdrawal. Satisfactory cardiac performance with oral long-acting nitrate were unsuccessful. However, the new oral vasodilator, prazosin hydrochloride, achieved considerable hemodynamic benefit by greatly reducing elevated left ventricular filling pressure and increasing severely depressed cardiac index to normal, accompanied by striking symptomatic improvement. Furthermore, long-term enhancement of cardiac dynamics and salutary functional status was maintained by ambulatory oral prazosin therapy for several months. This experience demonstrates the favorable alternative of prazosin nitroprusside-like actions over hydralazine-nitrate therapy in heart failure therapy and emphasizes prazosin's utility when untoward side effects to hydralazine develop.

Original languageEnglish (US)
Pages (from-to)819-820
Number of pages2
JournalArchives of Internal Medicine
Volume138
Issue number5
DOIs
StatePublished - 1978

Fingerprint

Hydralazine
Prazosin
Tachycardia
Heart Failure
Hemodynamics
Sodium
Nitrates
Nitroprusside
Swan-Ganz Catheterization
Therapeutics
Coronary Care Units
Digitalis
Ventricular Pressure
Ventricular Tachycardia
Vasodilator Agents
Diuretics
Coronary Disease

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy. / Laslett, L. J.; DeMaria, A. N.; Amsterdam, Ezra A; Mason, D. T.

In: Archives of Internal Medicine, Vol. 138, No. 5, 1978, p. 819-820.

Research output: Contribution to journalArticle

@article{48227a7de91341d588c7bb0be0b8cbbe,
title = "Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy",
abstract = "Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates. Coronary care unit admission with Swan-Ganz catheterization corrected hemodynamics by sodium nitroprusside treatment after hydralazine withdrawal. Satisfactory cardiac performance with oral long-acting nitrate were unsuccessful. However, the new oral vasodilator, prazosin hydrochloride, achieved considerable hemodynamic benefit by greatly reducing elevated left ventricular filling pressure and increasing severely depressed cardiac index to normal, accompanied by striking symptomatic improvement. Furthermore, long-term enhancement of cardiac dynamics and salutary functional status was maintained by ambulatory oral prazosin therapy for several months. This experience demonstrates the favorable alternative of prazosin nitroprusside-like actions over hydralazine-nitrate therapy in heart failure therapy and emphasizes prazosin's utility when untoward side effects to hydralazine develop.",
author = "Laslett, {L. J.} and DeMaria, {A. N.} and Amsterdam, {Ezra A} and Mason, {D. T.}",
year = "1978",
doi = "10.1001/archinte.138.5.819",
language = "English (US)",
volume = "138",
pages = "819--820",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Hydralazine-induced tachycardia and sodium retention in heart failure. Hemodynamic and symptomatic correction by prazosin therapy

AU - Laslett, L. J.

AU - DeMaria, A. N.

AU - Amsterdam, Ezra A

AU - Mason, D. T.

PY - 1978

Y1 - 1978

N2 - Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates. Coronary care unit admission with Swan-Ganz catheterization corrected hemodynamics by sodium nitroprusside treatment after hydralazine withdrawal. Satisfactory cardiac performance with oral long-acting nitrate were unsuccessful. However, the new oral vasodilator, prazosin hydrochloride, achieved considerable hemodynamic benefit by greatly reducing elevated left ventricular filling pressure and increasing severely depressed cardiac index to normal, accompanied by striking symptomatic improvement. Furthermore, long-term enhancement of cardiac dynamics and salutary functional status was maintained by ambulatory oral prazosin therapy for several months. This experience demonstrates the favorable alternative of prazosin nitroprusside-like actions over hydralazine-nitrate therapy in heart failure therapy and emphasizes prazosin's utility when untoward side effects to hydralazine develop.

AB - Severe tachycardia, ventricular ectopy, and sodium retention manifested by hemodynamic deterioration developed with hydralazine hydrochloride therapy in chronic coronary heart disease with congestive failure refractory to digitalis, diuretics, and nitrates. Coronary care unit admission with Swan-Ganz catheterization corrected hemodynamics by sodium nitroprusside treatment after hydralazine withdrawal. Satisfactory cardiac performance with oral long-acting nitrate were unsuccessful. However, the new oral vasodilator, prazosin hydrochloride, achieved considerable hemodynamic benefit by greatly reducing elevated left ventricular filling pressure and increasing severely depressed cardiac index to normal, accompanied by striking symptomatic improvement. Furthermore, long-term enhancement of cardiac dynamics and salutary functional status was maintained by ambulatory oral prazosin therapy for several months. This experience demonstrates the favorable alternative of prazosin nitroprusside-like actions over hydralazine-nitrate therapy in heart failure therapy and emphasizes prazosin's utility when untoward side effects to hydralazine develop.

UR - http://www.scopus.com/inward/record.url?scp=0018170882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018170882&partnerID=8YFLogxK

U2 - 10.1001/archinte.138.5.819

DO - 10.1001/archinte.138.5.819

M3 - Article

VL - 138

SP - 819

EP - 820

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 5

ER -